Business Context and Reporting Period
Palisade Bio, Inc. (PALI) filed a Current Report on Form 8-K on September 8, 2023, regarding events occurring on September 1, 2023. The filing discloses the entry into a Material Definitive Agreement and the completion of an asset acquisition via a Research Collaboration and License Agreement with Giiant Pharma Inc.
Key Financial Metrics
This filing does not contain specific financial statements, revenue, profit, cash flow, or debt figures. The document focuses on the terms of a strategic agreement rather than historical financial performance.
Material Changes and Agreement Terms
Acquisition of Licensed Assets
- Assets Acquired: Palisade received an exclusive, worldwide license (with sublicense rights) to develop, manufacture, and commercialize Giiant's assets, specifically the GT-2018 and GT-1908 compounds and associated intellectual property.
- Joint Development: A Joint Development Committee (JDC) was established with two Palisade appointees and one Giiant appointee to oversee development through the "Proof of Concept" stage.
- Cost Allocation: Prior to Proof of Concept, each party bears its own costs. Upon reaching Proof of Concept, Palisade assumes sole responsibility for all development, manufacturing, regulatory, and commercialization costs.
Payment Structure
- Milestone Payments: Palisade will make payments upon achieving development milestones, payable in cash or common stock at Palisade's election.
- Royalties: Ongoing royalty payments are due on sales or sublicenses of products derived from the Licensed Assets.
- Payment Cap: Total License Payments are subject to a cap that adjusts dollar-for-dollar based on aggregate development costs incurred by the parties.
- Right of First Refusal: Palisade holds a 30-day right of first refusal if Giiant attempts to sell or assign its rights to receive License Payments.
Termination Provisions
- Palisade Termination: Palisade may terminate for convenience (no further payments required), failure to achieve Proof of Concept within 18 months (payments may continue), or material breach by Giiant.
- Giiant Termination: Giiant may terminate only for material breach by Palisade, unless the Payment Cap is achieved, at which point the license becomes perpetual.
Guidance, Outlook, and Risks
The filing includes standard forward-looking statements regarding the company's cash runway, ability to develop licensed technologies, market potential, and regulatory approvals. Management highlights significant risks, including the uncertainty of clinical program advancement, the time-consuming regulatory approval process, and the need for additional financing to fund future operations. The company disclaims any obligation to update these forward-looking statements.
Investor Verification Checklist
- Verify the specific dollar amounts and timing of the development milestone payments in the full text of the License Agreement (Exhibit 10.01).
- Confirm the exact formula used to calculate the "Payment Cap" and its current status relative to development costs.
- Assess the company's current cash runway to determine if it can fund the sole responsibility for costs after the "Proof of Concept" stage is reached.
- Review the clinical status and data for the GT-2018 and GT-1908 compounds to evaluate the feasibility of the 18-month Proof of Concept timeline.
- Check for any subsequent filings regarding the issuance of stock for milestone payments or changes in the company's capital structure.